1. Home
  2. KRNT vs ABUS Comparison

KRNT vs ABUS Comparison

Compare KRNT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kornit Digital Ltd.

KRNT

Kornit Digital Ltd.

N/A

Current Price

$17.99

Market Cap

733.1M

Sector

Industrials

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.68

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNT
ABUS
Founded
2002
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
733.1M
839.5M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
KRNT
ABUS
Price
$17.99
$4.68
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$19.75
$5.00
AVG Volume (30 Days)
304.9K
1.3M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.84
Revenue
N/A
$14,083,000.00
Revenue This Year
$4.52
N/A
Revenue Next Year
$7.84
$239.71
P/E Ratio
N/A
$5.45
Revenue Growth
N/A
128.21
52 Week Low
$11.93
$3.35
52 Week High
$19.78
$5.38

Technical Indicators

Market Signals
Indicator
KRNT
ABUS
Relative Strength Index (RSI) 69.68 56.21
Support Level $13.97 $4.11
Resistance Level $19.78 $4.82
Average True Range (ATR) 0.75 0.15
MACD 0.25 0.03
Stochastic Oscillator 73.15 92.39

Price Performance

Historical Comparison
KRNT
ABUS

About KRNT Kornit Digital Ltd.

Kornit Digital Ltd is a developer and provider of digital solutions for the printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value-added services that enable large-scale printing of short-run complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink, and other consumables, and services, including software subscriptions. The company geographically operates in the U.S., EMEA, Asia Pacific, and other countries. It derives maximum revenue from the U.S.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: